- CEO
- Yu Quan Wang
- Full Time Employees
- 7,982
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Xinhua Medical Technology Park Zibo SD China 255086
- IPO Date
- Sep 27, 2002
- Business
- Shinva Medical Instrument Co., Ltd. (600587.SS) manufactures and markets medical devices, pharmaceutical equipment, and related healthcare solutions primarily in China with exports to over 110 countries and regions. Founded in 1943 and headquartered in Zibo, Shandong Province, the company offers infection control products including steam sterilizers such as the Tianxuan series, rapid formaldehyde sterilizers like the Qiming series, vacuum washer-disinfectors such as the Bengten series, and flexible endoscope washer-disinfectors like the Hanghai series; radiotherapy equipment featuring intelligent online adaptive systems with ring gantry structures; surgical instruments and orthopaedics tools encompassing standard, neuro, cardiovascular, laparoscopic, and orthopedic variants; operating room solutions including the STable-M8000 electric operating table driven by 16 DC motors and the SFace-pipe anesthesia circuit disinfector; dental equipment and consumables; in-vitro diagnostic reagents and instruments; biological materials and consumables; dialysis equipment such as hemodialysis products; and medical environmental protection systems like waste treatment and air purifiers. It also provides pharmaceutical machinery for large and small volume injections, freeze dryers, and aseptic systems; turnkey integrated solutions for CSSD, radiotherapy, digital operating rooms, infection control, pharmaceuticals, dental care, and experimental animal safeguards; and medical services with five overseas sales centers in Russia, Germany, Indonesia, Vietnam, and Egypt.
In recent developments, Shinva showcased innovations at the 91st CMEF in April 2025 and MEDICA 2025, highlighting smart healthcare solutions including the Qiming sterilizer validated for Da Vinci instruments and the SMors surgical behavior management system; received medical device registration certificates in 2025 for products such as steam sterilizers, X-ray CT equipment, disposable hemodialysis tubing, surgical sutures, and cleaning/disinfecting devices; announced in December 2024 the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology Co., Ltd. for RMB 166.5 million to expand into respiratory testing and enrich its product pipeline; reported first-half 2024 revenue of RMB 5.187 billion (up 2.24% year-over-year) and net profit of RMB 484 million (up 5.57%), with nine-month 2024 net profit of RMB 617 million (up 6.63%); and invested heavily in R&D, securing 85 new patents in 2025 (up 41.72% year-over-year) while committing to carbon neutrality by 2060.